Standard BioTools Inc.
LAB
$0.67
$0.022.68%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 84.60M | 86.26M | 85.33M | 86.31M | 88.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.60M | 86.26M | 85.33M | 86.31M | 88.85M |
| Cost of Revenue | 43.84M | 45.41M | 47.89M | 48.90M | 48.79M |
| Gross Profit | 40.75M | 40.85M | 37.44M | 37.42M | 40.06M |
| SG&A Expenses | 86.93M | 98.64M | 109.86M | 111.84M | 109.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.23M | 164.76M | 178.64M | 180.70M | 179.04M |
| Operating Income | -62.64M | -78.51M | -93.31M | -94.38M | -90.19M |
| Income Before Tax | -90.98M | -87.83M | -96.70M | -101.57M | -90.47M |
| Income Tax Expenses | -37.05M | -37.75M | -37.88M | -1.67M | -338.00K |
| Earnings from Continuing Operations | -53.93 | -50.08 | -58.83 | -99.90 | -90.14 |
| Earnings from Discontinued Operations | 138.84M | 128.29M | -16.07M | -28.35M | -30.37M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.91M | 78.21M | -74.90M | -128.25M | -120.50M |
| EBIT | -62.64M | -78.51M | -93.31M | -94.38M | -90.19M |
| EBITDA | -53.07M | -68.21M | -82.33M | -76.20M | -67.24M |
| EPS Basic | 0.22 | 0.20 | -0.20 | -0.34 | -0.32 |
| Normalized Basic EPS | -0.08 | -0.10 | -0.13 | -0.14 | -0.13 |
| EPS Diluted | 0.22 | 0.20 | -0.20 | -0.34 | -0.32 |
| Normalized Diluted EPS | -0.08 | -0.10 | -0.13 | -0.14 | -0.13 |
| Average Basic Shares Outstanding | 1.55B | 1.54B | 1.53B | 1.52B | 1.50B |
| Average Diluted Shares Outstanding | 1.55B | 1.54B | 1.53B | 1.52B | 1.50B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |